3GOLD Executive Committee[DB/OL].Guidelines:Global Strategy for Diagnosis,Management,and Prevention of COPD,November 2006[2006-11-18].http://www.goldcopd.com/Guidelineitem.asp? l1 =2-12 = 1&intId =989. 被引量：1
4Celli BR,MacNee W,Committee members.Standard for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946. 被引量：1
5Celli BR,Cote CG,Marin JM,ct al.The body mass index,airflow obstruction,dyspnea and exercise capacity index in chronic obstructive pulmonary disease.N Engl J Med,2004,350:1005-1012. 被引量：1
7Vincken W,van Noord JA,Greefhorst AP.,et al.Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium[J].Eur Respir J,2002,19(2):209 -216. 被引量：1
8Tashkin DP.The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease:how long-term studies contribute to our understanding[J].Am J Med,2006,119 (10 Suppl 1):63-72. 被引量：1
9Donohue JF,van Noord JA,Bateman ED,et al.A 6-month,placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol[J].Chest,2002,122(1):47-55. 被引量：1
10Tashkin DP,Cooper CB.The role of long-acting bronchodilators in the management of stable COPD[J].Chest,2004,125 (1):249 -259. 被引量：1
5CALVELEY P, PAUWELES R, VESTBO J, et al. Combbined meterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial[J]. Lancet, 2003, 361(99356): 449-456. 被引量：1
6BURGE PS, CELRLEY PMA, JONES PW, et al. Ranbmjsed double, blind placebo controlled study of fluticasone propionate in patients with moderatate to severe chronicob structive pul- monary disease; the ISOLDE trial [J]. BMJ, 2000, 320(72450): 1297-1303. 被引量：1
7SINGH D, BROOKS J, HAGAN G, et al. Superiority of "triple" therapy with salmeterol/fluticesone propionate and tiotrpium bro- mide versus individual components in moderate to severe COPD [J]. Thorax, 2008, 63: 592-598. 被引量：1
8TORU OGA MD, KOICHI NISHIMURA MD, MITSUHIRO TS- UKINO MD, et al. A comparison of the effects of salbutamol and Ipratropium bromide on exercise endurance in patients with COPD[J]. Chest, 2003, 123(6): 1810-1816. 被引量：1
9Rabe KF, Hurd S, Anzueto A, et al.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary[J]. Am J Respir Crit Care Med, 2007,176(6):532-555. 被引量：1
10Cosio MG, Saetta M, Agusti A.Immunologic aspects of chronic obstructive pulmonary disease[J]. N Engl J Med, 2009,360(23):2445-2454. 被引量：1
